EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?

Blond, Emilie; Disse, Emmanuel; Cuerq, Charlotte; Drai, Jocelyne; Valette, Pierre-Jean; Laville, Martine; Thivolet, Charles; Simon, Chantal; Caussy, Cyrielle

doi:10.1007/s00125-017-4264-9

Cited by 106 publications

(85 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study looking at various combinations of non‐invasive methods found comparable PPV for detecting F3‐F4 . The low PPV indicates the need to develop and use a combination of methods to detect fibrosis and (even more so) cirrhosis that rely on complementary and distinct principles …”

Section: Discussionmentioning

confidence: 99%

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement

Karlas¹,

Petroff²,

Sasso³

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement

Karlas¹,

Petroff²,

Sasso³

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…On the basis of the reported benefits of the MD components on the features of the MetS, including NAFLD, the MD has been proposed as the diet of choice for the dietary treatment of hepatic steatosis [74]. Herein, we report the current evidence on the liver-related outcomes of the MD diet.…”

Section: Current Evidence About the Effects Of The Mediterranean Dietmentioning

confidence: 97%

“…Interestingly, at a multiple linear-regression age-balanced analysis, the changes in AMDS were related to the reduction in hepatic fat content independently of physical activity. However, a potential limitation of this study is the fact that the BLS is not accurate in the staging of fatty liver and is indeed not included among the validated steatosis scores by the most recent EASL/EASD/EASO guidelines [74].…”

Section: Current Evidence About the Effects Of The Mediterranean Dietmentioning

confidence: 99%

Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered

et al. 2019

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is expected to become the leading cause of end-stage liver disease worldwide over the next few decades. In fact, NAFLD encompasses different clinical scenarios, from the simple accumulation of fat (steatosis) to steatohepatitis (NASH), NASH-cirrhosis, and cirrhosis complications. In this context, it is fundamental to pursue strategies aimed at both preventing the disease and reducing the progression of liver fibrosis once liver damage is already initiated. As of today, no pharmacological treatment has been approved for NAFLD/NASH, and the only recommended treatment of proven efficacy are life-style modifications, including diet and physical exercise pointing at weight loss of 5%–7%. Different dietetic approaches have been proposed in this setting, and in this review, we will discuss the evidence regarding the efficacy of the Mediterranean Diet as a treatment for NAFLD. In particular, we will report the effects on liver-related outcomes.

show abstract

“…A recent study also reports a novel pathway in which hepatic vitamin D receptor (VDR) expression is increased in patients with simple steatosis (nonalcoholic fatty liver without inflammation), and the activated VDR upregulates angiopoietin-like protein 8 (ANGPTL8) expression, thus contributing to triglyceride accumulation in human hepatocytes [115]. At any rate, studies have reported that fibrosis-initiated fatty liver disease progresses over many years, thus providing a potential window for intervention by examining diseaseprogression/modifying factors in NAFLD [116][117][118]. It is important to note that increased BMI and insulin resistance have been associated with a more rapid progression to fibrosis [35,119].…”

Section: The Genetics Of Nafldmentioning

confidence: 99%

The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Sherif¹

2019

Nonalcoholic Fatty Liver Disease - An Update

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) affects a third of the world's population and its rapid rise parallels the increase in hepatocellular carcinoma (HCC). NAFLD replacing hepatitis C virus (HCV) infection as a leading indicator for liver transplantation (LT) in the United States. NAFLD is a spectrum of disease ranging from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH), which can progress to advanced fibrosis (AF) and cirrhosis, culminating in HCC. The main clinical concern of public health administrators is that many patients who are unaware of NAFLD remain undiagnosed and risk developing end-stage liver disease (ESLD). Clinicians overly rely on surrogate liver enzymes to identify patients with NAFLD, allowing for substantial liver disease to go unnoticed and untreated. Furthermore, according to epidemiological studies, in patients diagnosed with NAFLD, ethnicity plays a role in complications and treatment response, and ethnic correlations with NAFLD are thoroughly underreported. Although liver biopsy is the gold standard method for appropriately diagnosing and staging NAFLD, most patients can be effectively diagnosed non-invasively with imaging modalities and integrated tests that are routinely available in the clinic today. This chapter discusses the current global rise in the rates of NAFLD and HCC; the current key findings incidences and the recommended diagnostic approaches and in therapeutic methods.

show abstract

EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?

Cited by 106 publications

References 11 publications

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement

Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered

The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Contact Info

Product

Resources

About